Oncopeptides is a pharmaceutical company focused on the development of therapies for difficult-to-treat hematological diseases. The company is headquartered in Stockholm, Sweden, and is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO. Oncopeptides North America operations is based in Mountain View, California.
Oncopeptides’ lead candidate melflufen is an investigational, first-in-class, peptide-drug conjugate that rapidly delivers a cytotoxic payload into tumor cells. Melflufen is rapidly taken up by myeloma cells due to its high lipophilicity and is immediately cleaved by peptidases to deliver an entrapped hydrophilic alkylator payload.
Melflufen is currently being evaluated for the treatment of relapsed/refractory multiple myeloma through a robust clinical program that includes multiple clinical studies currently underway, which include the pivotal phase 2 HORIZON study and phase 3 study OCEAN.
Visit the Clinical Studies page to learn more about these trials and Oncopeptides’ clinical development efforts. Additionally, company announcements and breaking news can be found on the Press Releases page.